Kura Oncology Inc Stock Price, News & Analysis

Kura Oncology has presented preclinical data showing the potential of menin inhibitors, specifically ziftomenib, in treating type 2 diabetes. The findings, shared at the American Diabetes Association’s 84th Scientific Sessions, highlight ziftomenib's ability to enhance pancreatic function, boost insulin production, and improve insulin sensitivity in preclinical models. Notably, the therapeutic effects persisted even after stopping the dose, indicating a possible restoration of beta-cell mass. Kura is also developing next-generation menin inhibitors targeting diabetes and other metabolic diseases, in addition to its ongoing clinical trials in acute leukemias.

Kura Oncology announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4). On June 3, 2024, the Compensation Committee awarded nonstatutory stock options to purchase 152,500 shares of common stock to eight new employees under the 2023 Inducement Option Plan. The exercise price for each option is $21.19 per share, matching the closing sales price on the grant date. The options vest over four years—25% after one year and the remainder monthly over the next 36 months, contingent on continued employment. These inducement awards aim to attract and retain talent effectively.

Kura Oncology, a clinical-stage biopharmaceutical company, has announced its participation in the Jefferies Global Healthcare Conference.

Troy Wilson, President and CEO, will engage in a virtual fireside chat on June 5, 2024, at 3:00 p.m. ET / 12:00 p.m. PT.

A live audio webcast and an archived replay will be accessible in the Investors section of Kura's website.

Kura Oncology has completed enrollment of 85 patients in its Phase 2 KOMET-001 clinical trial, targeting relapsed or refractory (R/R) NPM1-mutant acute myeloid leukemia (AML), within 16 months.

The trial focuses on assessing the clinical activity, safety, and tolerability of their menin inhibitor, ziftomenib (KO-539). Topline data is expected in early 2025.

Notably, ziftomenib has received Breakthrough Therapy Designation from the FDA, which aims to expedite the review process for new drug applications due to its potential efficacy in treating R/R NPM1-mutant AML.

This milestone underscores the urgent need for effective treatment options in AML and highlights ziftomenib's potential to become a best-in-class treatment.

Kura Oncology, Inc. (Nasdaq: KURA) will participate in Bank of America Securities 2024 Healthcare Conference, with the company's President and CEO scheduled for a virtual fireside chat. The event will take place on May 15, 2024, providing investors with insights into the company's progress and future prospects.

Kura Oncology, Inc. announced the granting of inducement awards in the form of nonstatutory stock options to six new employees under the 2023 Inducement Option Plan. The stock options will allow the purchase of 67,950 shares of common stock at an exercise price of $20.28 per share. The options will vest over four years, with 25% vesting after one year, and the rest vesting monthly over 36 months, contingent on the employees' continued service relationship.

Kura Oncology reported first quarter 2024 financial results, highlighting Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML, positive preliminary combination data, and first patient dosing with KO-2806 and cabozantinib. The company has $527 million in cash, cash equivalents, and investments, ensuring runway into 2027. Financially, research and development expenses increased to $36.3 million, while general and administrative expenses rose to $18.2 million. The net loss for Q1 2024 was $49.5 million. Management expects current funds to last into 2027.